2008 - Factores de crecimiento hematopoyético-Dr. A. Biete - GICOR
2008 - Factores de crecimiento hematopoyético-Dr. A. Biete - GICOR
2008 - Factores de crecimiento hematopoyético-Dr. A. Biete - GICOR
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
High dose recombinant human<br />
erythropoietin use is associated with<br />
increased overall survival in patients with<br />
mutipe myeloma<br />
• High dose, long term erythropoietin use is<br />
associated with longer survival in patients with<br />
multiple myeloma and anemia. anemia<br />
• The findings can be explained by a direct or<br />
indirect anti-myeloma<br />
anti myeloma effect of human<br />
erythropoietin.<br />
erythropoietin<br />
• A randomized controlled trials is nee<strong>de</strong>d to<br />
corroborate these findings. findings<br />
From BAZ R, abst 6621, ASCO 2005
Change language